Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $260.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective increased by Jefferies Financial Group from $230.00 to $260.00 in a report issued on Tuesday,Benzinga reports. They currently have a hold rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also recently issued reports on ALNY. JPMorgan Chase & Co. decreased their price objective on shares of Alnylam Pharmaceuticals from $400.00 to $375.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Weiss Ratings upgraded Alnylam Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, July 31st. Wells Fargo & Company reduced their price target on Alnylam Pharmaceuticals from $316.00 to $256.00 and set an “equal weight” rating for the company in a research report on Friday, August 14th. Sanford C. Bernstein reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, August 31st. Finally, Raymond James Financial upgraded Alnylam Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $420.00 price target for the company in a research note on Monday, August 3rd. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $376.67.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY opened at $247.51 on Tuesday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05. The firm has a market cap of $33.12 billion, a PE ratio of 46.01 and a beta of 0.31. The firm’s 50 day moving average price is $255.71 and its 200 day moving average price is $289.27. Alnylam Pharmaceuticals has a twelve month low of $197.81 and a twelve month high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, topping the consensus estimate of $1.63 by $0.21. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The company had revenue of $1.29 billion during the quarter, compared to the consensus estimate of $1.32 billion. During the same period in the previous year, the firm posted ($0.51) earnings per share. The company’s revenue for the quarter was up 66.9% compared to the same quarter last year. As a group, research analysts expect that Alnylam Pharmaceuticals will post 6.71 EPS for the current fiscal year.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several large investors have recently made changes to their positions in ALNY. Daiwa Securities Group Inc. raised its holdings in Alnylam Pharmaceuticals by 0.3% during the second quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock worth $4,220,000 after buying an additional 35 shares during the last quarter. Golden State Wealth Management LLC grew its holdings in shares of Alnylam Pharmaceuticals by 100.0% during the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 36 shares during the last quarter. Coldstream Capital Management Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 2.4% during the third quarter. Coldstream Capital Management Inc. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $748,000 after buying an additional 38 shares during the last quarter. Laird Norton Wetherby Wealth Management LLC increased its position in shares of Alnylam Pharmaceuticals by 3.3% during the third quarter. Laird Norton Wetherby Wealth Management LLC now owns 1,266 shares of the biopharmaceutical company’s stock worth $577,000 after acquiring an additional 40 shares in the last quarter. Finally, Atlantic Union Bankshares Corp raised its holdings in shares of Alnylam Pharmaceuticals by 20.9% in the 4th quarter. Atlantic Union Bankshares Corp now owns 231 shares of the biopharmaceutical company’s stock worth $92,000 after acquiring an additional 40 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi) technology. RNAi therapies are designed to silence specific genes involved in disease, offering a way to target conditions that may be difficult to treat with conventional drug approaches. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam’s commercial products include Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Amvuttra (vutrisiran).